GERMANY - Novo Nordisk Biotech Fund brings total raised in Affimed to EUR 30m

The money raised in this series-B financing will be used to fund Affimed’s proprietary therapeutic antibody programmes. Based on its proprietary TandAb tetravalent antibody format, the company will focus specifically on the two clinical lead programs, a TandAb for the treatment of Hodgkin’s disease and another for the treatment of Non-Hodgkin’s Lymphoma (NHL). Affimed also plans to advance additional pre-clinical antibody programs for various other oncology and anti-inflammatory indications.

Affimed is a biopharmaceutical company based in Heidelberg, specialising in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May 2000 by Professor Melvyn Little as a spin-off of his group Recombinant Antibodies at the German Cancer Research Centre in Heidelberg.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH